Bone Biologics Files Patent Application for Bone Regeneration Technology
BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation ('Bone Biologics' or the 'Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein.
The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions.
'This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients,' said Jeffrey Frelick, Chief Executive Officer of Bone Biologics.
The patent application, if approved, will strengthen Bone Biologics' intellectual property portfolio and support the Company's strategic plan to advance the clinical development program.
About Bone Biologics Corp.
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements regarding the expected timing, implementation, and success of the Company's patent application and pilot clinical study, the ability of the Company's lead product candidate NB1 to provide rapid, specific and guided control over bone regeneration and show fusion success in humans, the ability of NB1 to compete in global markets, as well as statements containing the words 'will,' 'mission,' 'plan,' and words of similar import, constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Tesla's Robotaxi Dream Is Here--But Alphabet May Have Already Won the Race
Tesla (NASDAQ:TSLA) just kicked off its robotaxi experiment in Austin. The service runs a handful of Model Y SUVs between 6 a.m. and midnight, priced at just $4.20 per ride. These cars are outfitted with Tesla's latest full-self-driving software, but each one still has a company employee riding shotgun. It's a soft launch, in a small area, for a few handpicked riders. The bigger promisethe Cybercab that Elon Musk unveiled in 2023isn't expected until 2026. Yet, this early-stage rollout sits under a $1.1 trillion market cap and a forward P/E of roughly 150, according to FactSet. For context: that's more than the combined value of the next 20 automakers. RBC's Tom Narayan believes robotaxis account for about 60% of Tesla's valuation. In other words, this bet matters. Warning! GuruFocus has detected 6 Warning Sign with META. But while Tesla grabs headlines, WaymoAlphabet's (NASDAQ:GOOG) self-driving armis already operating in five cities, including a new launch in Atlanta. Its 1,500-vehicle fleet is real, driverless, and growing. A new Arizona plant is set to more than double that by end of next year. Waymo raised $5.6 billion last year at a $45 billion valuation, but analysts are getting more bullish. Raymond James' Josh Beck now pegs Waymo closer to $150 billion, citing a base-case of 129% compound annual growth in gross bookings over five years. A recent Uber partnership could push those numbers even higher. The market might still be fixated on Tesla's bold visionbut Waymo's quietly building a commercial robotaxi empire. Tesla's edge? Its bet on software. Musk is aiming to transform existing Teslas into money-making robotaxis with a simple updateno Lidar, just cameras. It's a cheaper approach, but not without issues. Sunlight glare, social media footage of driving errors, and early questions from regulators have already surfaced. And at $4.20 per ride, the economics don't yet impress. Waymo, meanwhile, is logging real miles, real data, and real revenue. Investors chasing the next big thing might want to look again. Because the under-the-radar AI moonshot may not be Teslait might be hiding inside Alphabet. This article first appeared on GuruFocus.
Associated Press
35 minutes ago
- Associated Press
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial
SAN FRANCISCO, June 27, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025. The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company's announcement that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease. Hagens Berman urges Rocket Pharmaceuticals investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Feb. 27, 2025 – May 26, 2025 Lead Plaintiff Deadline: Aug. 11, 2025 Visit: Contact the Firm Now: [email protected] 844-916-0895 The Rocket Pharmaceuticals, Inc. (RCKT) Securities Class Action: The litigation focuses on the propriety of Rocket Pharmaceutical's disclosures about the trial protocol being implemented in the RP-A501 Phase 2 trial. More specifically, the complaint alleges that Rocket Pharmaceuticals made materially false and misleading statements while failing to disclose to investors: (1) the true state of RP-A501's safety and clinical trial protocol; (2) that the company knew Serious Adverse Events ('SAEs'), including patient's deaths, were at risk; and (3) that the company amended the trials protocol to introduce a novel immunomodulatory agent to the pretreatment regimen. Investors learned the truth on May 27, 2025, when the company revealed that the FDA put a clinical hold on its Phase 2 study after a patient suffered a SAE and ultimately died. During the May 27, 2025 update call, in response to analysts' questions, management revealed that the company amended the trial protocol 'several months ago[.]' The analysts were seemingly unaware of the company's amendments before this update call. This news drove the price of Rocket Pharmaceutical's shares crashing $3.94 (-62%) the same day. 'We're investigating claims that Rocket Pharmaceuticals may have misled investors about its Phase 2 protocol and whether it secretly amended it without first notifying the FDA and investors,' said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in Rocket Pharmaceuticals and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Rocket Pharmaceuticals case and our investigation, read more» Whistleblowers: Persons with non-public information regarding Rocket Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895
Gizmodo
35 minutes ago
- Gizmodo
This Once-a-Month Ozempic Rival Just Delivered Big Results
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves once each week. In newly released clinical trial data, Amgen's once-monthly experimental drug MariTide performed as well as or even better than the existing blockbuster GLP-1 medications semaglutide and tirzepatide. People taking MariTide consistently lost more weight than those on placebo, with some losing up to 20% of their baseline weight over a year's time. Amgen is moving ahead to Phase III trials of MariTide, setting the stage for a fierce competition among the next generation of obesity drugs. Amgen presented the full results of its Phase II trial of MariTide this week at the annual American Diabetes Association meeting; the results were also published in the New England Journal of Medicine. Ozempic Might Be a Dementia Buster, Too Like semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro) before it, MariTide mimics GLP-1, a hormone important to regulating our hunger and blood sugar. But the injectable medication has a few new tricks up its sleeve. The drug additionally carries a molecule that targets GIP, another important hunger-related hormone. Interestingly enough, tirzepatide mimics GIP, but MariTide inhibits it (that suggests GIP's role in controlling our weight is plenty complicated). The experimental drug also contains a lab-made antibody designed to keep it lingering in our system for a long time, so it's intended to be taken monthly or once every two months, compared to the weekly shots needed for semaglutide and tirzepatide. The Phase II trial involved nearly 600 adults, some of whom had type 2 diabetes and others with only obesity. In those with obesity only, people lost up to 20% of their weight on average over a 52-week span (those on placebo lost an average of 2.6% body weight). People with type 2 diabetes lost on average up to 17% of their weight. These results, while not directly comparable at this point, are on par with the clinical trial data of the latest GLP-1 drugs. And since participants were still continuing to shed pounds by the study's end, it's possible that the typical weight loss seen with MariTide might be even higher. 'MariTide delivered strong efficacy, including sustained weight loss without a plateau in the 52-week Phase 2 study and meaningful improvements in cardiometabolic risk factors, representing a defining advance for the obesity field,' said Jay Bradner, executive vice president of research and development at Amgen, in a statement from the company. Not everything with MariTide is sunshine and puppies, however. Rates of vomiting were much higher among certain groups of people on MariTide, for instance, which likely contributed to a higher rate of people dropping out before the study's end. But some data also suggest this side effect can be dampened by gradually raising people's doses over time, similar to how existing GLP-1 drugs are managed. The Best Obesity Drugs Aren't Even Here Yet Amgen will fully test out this staggered dosing strategy in its Phase III 72-week-long trial of MariTide for people with obesity and Type 2 diabetes, which has already begun enrollment. The company also plans to launch Phase III trials for cardiovascular disease, sleep apnea, and heart failure. But it's far from alone in the arms race to develop more effective or practical obesity treatments. Dozens of other candidates are in the pipeline, each with their own possible advantages over today's drugs, such as being available via a pill or coming without the gastrointestinal side effects common to GLP-1s. Not all of these experimental drugs will work out, of course, but it seems likely that semaglutide and tirzepatide soon won't be the only options available for people with obesity.
